Abstract Two new diorganotin(IV) complexes with the general formula (RC7H6)2Sn(L) (where RC7H6 = p-ClBn, C1; and p-FBn, C2) were prepared based on the reaction of 2,3-bis(4-hydroxysalicylidene-amino)-maleic nitrile (L) with substituted dibenzyltin(IV) dichloride. The structures were confirmed by elemental analysis, Fourier transform infrared (FT-IR), proton and carbon nuclear magnetic resonance (1H and 13C NMR). They were tested against several cancer cell lines by using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. C1, which was most effective against MCF-7 breast cancer cell line, was further investigated in formulation and encapsulation studies, including drug encapsulation efficiency, particle size, morphology and in vitro drug release. An encapsulation of about 90% was achieved with particles of 128 nm average diameter. Field emission scanning electron microscopy (FESEM) confirmed a spherical shape for the encapsulated C1. The cumulative drug release over a period of 60 days in phosphate buffered saline (PBS) at pH 7.4 was 75%. Based on these results, the formulated drug has the potential of a slow release drug for cancer chemotherapy.

中文翻译：

---

N,Nʹ-(1, 2-dicyano-1,2-vinylene)-bis(4-hydroxysalicylideneaminato) di(p-chlorobenzyl)tin 作为潜在抗癌药物的合成、结构表征、细胞毒性和包封研究

摘要 基于 2,3-bis(4) 的反应，制备了两种具有通式 (RC7H6)2Sn(L)（其中 RC7H6 = p-ClBn，C1；和 p-FBn，C2）的新型二有机锡 (IV) 配合物。 -羟基水杨基-氨基)-马来腈(L)与取代的二苄基锡(IV)二氯化物。通过元素分析、傅里叶变换红外光谱 (FT-IR)、质子和碳核磁共振 (1H 和 13C NMR) 确认了结构。通过使用 MTT（3-（4,5-二甲基噻唑-2-基）-2,5-二苯基溴化四唑）测定法对它们进行了针对几种癌细胞系的测试。C1 对 MCF-7 乳腺癌细胞系最有效，在制剂和包封研究中得到进一步研究，包括药物包封效率、粒径、形态和体外药物释放。平均直径为 128 nm 的颗粒实现了约 90% 的包封。场发射扫描电子显微镜 (FESEM) 证实封装的 C1 呈球形。在 pH 7.4 的磷酸盐缓冲盐水 (PBS) 中，60 天的累积药物释放为 75%。基于这些结果，配制的药物具有作为癌症化疗缓释药物的潜力。